Feed KRRO
KR

Korro Bio, Inc.

KRRO · NASDAQ

$14.07 +1.44% (+$0.20)
1M +7.08%
Market Cap $140.0M
P/E Ratio -
Div. Yield -
ROE 114.26%
Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/S 58.79x
P/B 1.36x
P/E N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Gross margin 72.75%
Net margin 4,477.08%
FCF margin 2,865.87%
Quality
0 /100
Poor
ROIC 49.60%
ROE 114.26%
Asset turnover 0.01x
Debt
94 /100
Low
Debt/Equity 0.41x
Current ratio 9.55x
Int. coverage N/A
Stability
9 /100
Unstable
Beta 2.25x
EPS volatility 65.13%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre KRRO
Online

Despre companie

Korro Bio, Inc. (KORO) is an American biotechnology company focused on developing innovative therapeutic approaches in the field of gene therapy and gene editing. With the goal of treating genetic diseases and other complex illnesses using advanced CRISPR technologies and gene editing, Korro Bio is a key player in the biomedicine sector. The company develops therapeutics aimed at modifying the genetic code, which may lead to new treatment options for patients. Korro Bio collaborates with leading scientific institutions and pharmaceutical companies to accelerate the development and commercialization of its products. Korro Bio, Inc. (KORO) shares could be suitable for investors looking to invest in biotechnology with potential for revolutionary advancements in treating genetic diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Ram Aiyar

Employees

57

Headquarters

Cambridge

Evenimente viitoare

11 NOV.

Earnings

Upcoming earnings report

56d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.